Equity Research, Broker Reports, and media content on Rex Bionics

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Rex Bionics
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 03 May 17
Small Cap Breakfast

Velocity Composites—Schedule 1. Manufactures advanced carbon fibre and ancillary material kits (predominantly carbon fibre) for use in the production of aircraft. Mid May admission expected. Offer details TBC. Shearwater Group—Schedule 1. Acquiring SecureEnvoy for £20m in cash and shares—a provider of multifactor authentication enterprise software solutions. RTO under the AIM rules. ADES International— Provider of offshore and onshore oil and gas drilling and production services in the Middle

Companies: PEN AAU UKOG RXB IHC AHCG SLNCF

Hybridan
  • 05 Dec 16
Small Cap Breakfast

Big Sofa Technologies— Schedule 1 from the b2b technology company providing video analytics at an enterprise level. Seeking to complete RTO of unlisted HubCo investments. Raising £6.1m. Target date 19 December. ECSC—Schedule 1 from provider of cyber security services. Raising £5m. Vendor sale £0.8m. Target date 14 Dec. Expected market cap £15m. RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Creo Medical Group

Companies: NWT C21 EAH HUW ONEV PYC CYAN RXB AHCG

Hybridan
  • 18 Nov 16
AIM Breakfast

The Mission Marketing Group (TMMG.L) | Rex Bionics (RXB.L) | Frontier Developments (FDEV.L) | W Resources (WRES.L) | Netscientific (NSCI.L) | President Energy (PPC.L) | CPP Group (CPP.L) | Eagle Eye Solutions Group (EYE.L) | Dorcster (DAR.L) | Avesco (AVS.L)

Companies: AVS TMG FDEV XPF EYE RXB CPP EMVC PPCGF

Hybridan
  • 24 Oct 16
AIM Breakfast

Fusionex International (FXI.L) | Rex Bionics (RXB.L) | Crossrider (CROS.L) | Cerillion (CER.L) | Sunrise Resources (SRES.L) | Premier Asset Management Group (PAM.L) | Faron Pharma (FARN.L) | Frontera Resources Corp (FRR.L) |

Companies: FARN SRES RXB CER PMI FXI FRR

Hybridan
  • 30 Aug 16
AIM Breakfast

CONCURRENT TECHNOLOGIES (CNC LN) | ELLERSTON GLOBAL INVESTMENTS (EGI AU) | ITM POWER (ITM LN) | LXB RETAIL PROPERTIES PLC (LXB LN) | OSIRIUM TECHNOLOGIES PLC (OSI LN) | P2P GLOBAL INVESTMENTS PLC (P2P LN) | PETRO MATAD LTD (MATD LN) | REX BIONICS PLC (RXB LN) | SAN LEON ENERGY PLC (SLE LN) | SOUND ENERGY PLC (SOU LN)

Companies: EGI CNC ITM SOU PSSL RXB MATD LXB SZX1

Hybridan
  • 26 Aug 16
AIM Breakfast

CONCURRENT TECHNOLOGIES (CNC LN) | ITM POWER (ITM LN) | LXB RETAIL PROPERTIES PLC (LXB LN) | OSIRIUM TECHNOLOGIES PLC (OSI LN) | P2P GLOBAL INVESTMENTS PLC (P2P LN) | PETRO MATAD LTD (MATD LN) | REX BIONICS PLC (RXB LN) | SAN LEON ENERGY PLC (SLE LN) | SOUND ENERGY PLC (SOU LN)

Companies: CNC ITM SOU PSSL RXB MATD LXB SZX1

Hybridan
  • 18 Aug 16
AIM Breakfast

Physiomics* (PYC.L) | Tricor (TRIC.L) | Concepta (CPT.L) | Akers Biosciences (AKRL) | Rex Bionics (RXB.L) | Empresaria Group (EMR.L) | YOLO Leisure & Tech (YOLO.L) | Nostra Terra Oil and Gas (NTOG.L) | EG Solutions (EGS.L) | Hydro Dec Group (HYR.L)

Companies: EMR EGS RXB AKR

Hybridan
  • 06 Jan 16
Initial orders point to start of commercialisation

Rex Bionics, a pioneer in the medical exoskeleton field, has recently reported a number of encouraging updates, including interim financial results, new distributors for the key US and China markets and positive interim metrics from its RAPPER II clinical trial. The company is focused on rehabilitating and improving mobility in patients with spinal cord injury. Its two key markets are rehabilitation centres and home use. Clinical trials demonstrating the medical benefits to patients and commerci

Companies: Rex Bionics

Edison
  • 01 Dec 15
RAPPER II first cohort generates positive results

Rex Bionics' RAPPER II clinical trial interim data were presented at the Australia and New Zealand Spinal Cord Society meeting last week. Trial interim results show that the Rex unit is safe for patient use. Positive RAPPER II results are expected to facilitate the company’s commercialisation strategy for the Rex exoskeleton. We will revisit our forecasts following H1 results in December.

Companies: Rex Bionics

Edison
  • 17 Jun 15
RAPPER II trial off to a good start

RAPPER II is a 100-patient study to measure the time taken for wheelchair users to mobilise in a Rex unit and complete an exercise regime. The study also intends to provide a better understanding of the severity of injury that can be safely treated with a Rex unit. The first patient has successfully completed the assessment and the data from the first cohort of patients are expected to be presented before the end of 2015. Trials such as this and RAPPER I, are key to driving adoption and therefor

Companies: Rex Bionics

Edison
  • 01 Jun 15
Executive Interview - Rex Bionics
executive-interview-rex-bionics-01-06-2015

Rex Bionics

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Rex Bionics. We currently have 10 research reports from 2 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
30May17 07:30 RNS Suspension - Rex Bionics Plc
26May17 16:31 RNS Holding(s) in Company
26May17 07:00 RNS Completion of Business Transfer & Refinancing
25May17 10:39 RNS Holdings in Company
25May17 10:38 RNS Holdings in Company
22May17 12:23 RNS Results of General Meeting
03May17 07:00 RNS Restructuring and New Investment
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Rex Bionics

  • Providers covering

    Rex Bionics

Frequently asked questions